Testicular cancer is the most common malignancy of young males aged 15 to 34 years. Its incidence has approximately doubled worldwide over the past 40 years, without a clear etiology for the observed rise. 1 Although 7200 new testis cancer diagnoses were expected in 1997, the cancer deaths were estimated to be about 350. 2 More than 90% of males newly diagnosed with good-risk germ cell tumors are cured with present day conventional multimodality therapy.
Once relapse occurs or if primary remission is never achieved, the prognosis significantly worsens. Second-and third-line chemotherapy (consisting of ifosfamide, velban or etoposide, and cisplatin) can salvage 15-25% of these patients, often with surgical resection of residual viable disease, teratoma, or necrotic masses. 1, [3] [4] [5] [6] Patients who fail to achieve complete response to prior chemotherapy or who present with extragonadal mediastinal primary sites fare particularly poorly.
A number of institutions have retrospectively reviewed response to primary multimodality therapy in an effort to determine factors prognostic for prolonged survival. [7] [8] [9] [10] To obtain consensus and develop a simple clinically based prognostic classification system, the International Germ Cell Cancer Collaborative Group (IGCCCG) provided clinical data on more than 5800 metastatic germ cell tumors treated with cisplatin-containing chemotherapy. 11 Integration of adverse prognostic factors (mediastinal primary site, degree of tumor marker elevation, nonpulmonary visceral metastases) produced three groupings: good prognosis, comprising 60% of germ cell tumors with 91% 5-year survival; intermediate prognosis, 26% of germ cell tumors with 79% 5-year survival; and poor prognosis, 14% of germ cell tumors (all nonseminomas) with 48% 5-year survival.
For patients with favorable characteristics, investigators have explored clinical trial designs which minimize toxicity and maintain therapeutic efficacy. [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] For those with poor prognostic features, who never achieve complete response, or who relapse after primary therapy, high-dose chemotherapy with autologous stem cell support has been administered with the hope of improving outcome. In 1986 Indiana University initiated a phase I/II tandem transplant trial, using high-dose carboplatin and etoposide with autologous bone marrow support, for patients with multiply relapsed Bone Marrow Transplantation or cisplatin-refractory disease. 22 Employing tandem cycles of high-dose carboplatin might serve as a means of overcoming cisplatin resistance, and thus test the importance of dose intensity in the treatment of testicular cancer. While treatment-related mortality (21%) was high in that initial trial, durable complete remissions were obtained in a small minority of patients who otherwise would have succumbed to their disease.
In 1990, the University of Michigan instituted a phase I/II tandem high-dose carboplatin and etoposide trial, with autologous marrow and/or peripheral blood progenitor cell (PBPC) support, for relapsed or cisplatin-refractory germ cell tumors. 23 This report summarizes our experience in 29 patients, and documents long-term durable remissions in 28% after high-dose chemotherapy and surgical resection of residual masses.
Patients and methods

Patient selection
Men (18 to 70 years of age) with histologically or serologically diagnosed, relapsed or refractory, germ cell tumors were eligible if hepatic (bilirubin, SGOT р1.5 × normal), renal (creatinine р1.6 mg/dl or creatinine clearance у50 ml/min), cardiac (ejection fraction у45%), and pulmonary (FEV 1.0 and DLCO у50% predicted for age) functions and performance scores (ECOG 0-2) were within normal limits. Extragonadal primary tumors and treated central nervous system (CNS) disease were also eligible. Significant hypocellularity or tumor depicted on bone marrow biopsy were exclusion criteria. All patients gave written informed consent. The study was conducted with the approval of the Institutional Review Board of the University of Michigan Medical Center.
Treatment plan (Figure 1)
Bone marrow harvest, leukapheresis and cyopreservation: Autologous marrow was harvested after complete recovery from conventional chemotherapy. A minimum of 2 × 10 8 mononuclear cells/kg body weight, divided into two
Bone marrow harvest and/or G-CSF mobilized PBPC
ABMT I
Carboplatin 15002100 mg/m2 total dose Etoposide 12002250 mg/m2 total dose with marrow and/or PBPC + G-CSF
ABMT II
Carboplatin 15002100 mg/m2 Etoposide 12002250 mg/m2 with marrow and/or PBPC + G-CSF equal doses, was collected and cryopreserved. Autologous PBPC were given in place of or with marrow, especially for those patients with an inadequate marrow harvest or who received prior pelvic irradiation. Patients received granulocyte colony-stimulating factor (G-CSF), 16 g/kg/day in divided doses for 3 days, and then underwent leukapheresis. A harvest target of two equal doses of 3.0 × 10 8 mononuclear cells/kg body weight of PBPC was collected and cryopreserved. ). Marrow and/or PBPC were infused 72 h after completing chemotherapy (day 0). G-CSF (5 g/kg/day subcutaneously) was begun on day 0, and continued until an absolute neutrophil count (ANC) у1000/l was achieved. Reverse isolation was maintained until an ANC Ͼ500/l for two determinations was reached. Prophylactic oral antibiotics and acyclovir were begun on day −6 and continued until the ANC reached 500/l. With neutropenic fever, broad-spectrum intravenous antibiotics were instituted. All patients received irradiated (2500 rad) blood and platelets. Packed red blood cells (RBC) were routinely given for a hemoglobin Ͻ8 g/dl and platelets for counts Ͻ10 000/l. All patients were eligible for a second course of high-dose carboplatin and etoposide if disease progression was not documented after the first transplant, and complete recovery of hematopoiesis (ANC у500/l and platelets Ͼ50 000/l) and nonhematologic toxicities had occurred. Patients with chemosensitive disease experiencing reversible grade III/IV nonhematologic toxicity were eligible to receive the second transplant with reduced doses of carboplatin (total dose 1050 mg/m 2 ) and etoposide (total dose 900 mg/m 2 ). Every attempt was made to begin the second course no later than 3 weeks after discharge from the first transplant.
ABMT
Post-ABMT surgery or radiotherapy:
Patients with residual disease by radiologic evaluation (regardless of tumor marker status) were considered for surgical resection or radiotherapy. Response was coded based on pathologic findings of the resected specimen.
Definition of terms
Disease status: Patients with chemotherapy sensitive relapsed germ cell tumors needed to demonstrate either a one-log reduction in serum tumor markers or a у50% reduction in sites of measurable disease. Refractory disease was defined as: (1) progressive disease while receiving initial cisplatin or within 4 weeks of the last dose of cisplatin (absolutely refractory); or (2) relapse after at least two prior platinum-based chemotherapy regimens (chemoresistant disease).
Hematologic and tumor response criteria: Time to hematologic reconstitution was measured from day 0 to recovery of an ANC у500/l, a platelet count у20 000/l, and a hematocrit Ͼ25%, independent of transfusions. Lesions were measured by physical examination and imaging studies, and tumor marker levels obtained, prior to marrow harvest and after recovery from each transplant. Complete (CR) or partial response (PR) was defined as the disappearance of all measurable tumor and marker elevations or a 50-99% reduction in the product of the bidimensional measurements, respectively, for a minimum of 4 weeks. A serologic PR was defined as at least a one-log reduction (10-fold drop) of a previously abnormal ␤HCG and a Ͼ50% decrease in AFP lasting at least 1 month. CR/surgically no evidence of disease (necrosis) applied to surgical specimens in which necrotic tumor, but no viable germ cell elements, was found. PR/surgically no evidence of disease (teratoma) applied to patients rendered diseasefree, but whose surgical specimens revealed viable germ cell elements. Stable disease (SD) reflected tumor regression not fulfilling the requirement for PR or Ͻ25% increase in bidimensional measurements. Disease progression (DP) was defined as a Ͼ25% increase in tumor size, the appearance of new lesions, and/or any rise in tumor markers.
Statistical analysis
Descriptive statistics were reported as frequencies or medians. Overall survival (OS) and disease-free survival (DFS) were defined as the time from the initiation of highdose chemotherapy (day 1 of ABMT I) to death and disease progression, respectively. OS and DFS curves were estimated by the Kaplan-Meier product limit method. 24 Greenwood's formula was used to calculate the standard errors of the DFS and OS curves. 25 Differences in OS and DFS by age at ABMT and number of transplants were estimated by Cox regression techniques.
Results
Patient characteristics (Table 1)
From August 1990 to June 1998, 29 men entered the study. Data available as of 1 November 1999, at a median observation time of 73 months (range, 16-111) from day 1 of the first cycle of high-dose chemotherapy, were used for this analysis.
Initial diagnosis and treatment:
All patients were diagnosed (median age 27 years) with germ cell tumors of gonadal or retroperitoneal origin. Twenty-five were nonseminomas and four were pure seminomas. By the American Joint Committee on Classification standards, one patient Twenty-six (90%) patients were treated with a median of four cycles of adjuvant platinum-based combination chemotherapy, and 16 of these received bleomycin, etoposide, and cisplatin (BEP). Three (10%) received no adjuvant chemotherapy.
Relapse and salvage therapy: Six patients had disease refractory to initial chemotherapy. Twenty-three others subsequently relapsed, the median disease-free interval from primary diagnosis to first recurrence being 9 months (range, 5-81). Prominent metastatic sites included abdominopelvic adenopathy (72%), lung (66%), mediastinal/hilar adenopathy (24%), liver (24%), CNS (21%), and cervical/ supraclavicular adenopathy (17%).
Including initial and salvage chemotherapy, 29 patients received a median of seven (range, 4-12) cycles of conventional chemotherapy prior to ABMT. Twenty-two patients were treated with two different regimens and four others received three. Of the chemotherapy regimens employed, 90% were cisplatin-based combinations, 8% were carboplatin-containing combinations, and 2% consisted of oral etoposide.
Sixteen patients underwent surgery apart from initial orchiectomy. Fourteen received a retroperitoneal lymph node dissection, nine as adjuvant therapy and five as surgical salvage (one teratoma, four carcinomas). Seven patients underwent thoractomy (three teratomas, two carcinomas, two necrotic masses), two received craniotomies for CNS metastases, and four underwent other surgical procedures for persistent disease (nephrectomy, skin nodule resection, cervical node dissection). Five patients received local radiotherapy pre-transplant, four for CNS metastases.
Disease status at time of transplant:
The median age at time of ABMT was 31 years (range, . The median time from primary diagnosis to day 1 of first transplant was 14 months (range, 4-134).
Of the 29 patients who underwent transplant, 16 received no further attempt at conventional cytoreduction, but proceeded to high-dose chemotherapy. At the time of ABMT, 10 remained chemosensitive, four were chemoresistant, 10 were absolutely refractory, and five were untested to platinum-based chemotherapy. Disease status (No. patients) at time of first transplant included: primary refractory disease (six), first relapse (10), second relapse (eight), third relapse (four), and fourth relapse (one). ). There was no clear relationship between escalating doses of chemotherapy and incidence of renal insufficiency or hearing loss. Doses higher than 2250 mg/m 2 of etoposide and 2100 mg/m 2 of carboplatin were not attempted to avoid a treatment-related mortality greater than 10%.
There were three (10%) multisystem treatment-related deaths. Two patients had received the highest total doses of chemotherapy (etoposide 2250 mg/m 2 , carboplatin 2100 mg/m 2 ) and one the lowest (etoposide 1200 mg/m 2 , carboplatin 1500 mg/m 2 ). All three patients developed primary renal failure (two requiring hemodialysis); two became obtunded with one dying of CNS hemorhage due to coagulopathy; and two developed respiratory failure. Although two of these patients had persistent fevers, none had documented sepsis.
Hematologic recovery: The median days of an ANC Ͻ500/l and of platelet counts Ͻ20 000/l were 11 (range, 7-31) and 12 (range, 3-32+), respectively. Patients required a median of seven units (range, 0-18+) of packed RBC and 36 units (range, 10-108+) of platelets until hematologic recovery.
Non-hematologic toxicity: Fourteen (48%) patients developed mild to severe stomatitis and/or esophagitis requiring analgesia. Seven (24%) experienced profound hearing loss, most likely carboplatin-related. Six patients had elevation of liver function tests (LFTs), four developed renal insufficiency (two required hemodialysis), four had severe diarrhea, and three experienced significant peripheral neuropathy. Eleven patients (No.) developed bacteremias due to Staphylococcus (five), Streptococcus (four), Pseudomonas (one), and Acinetobactor (one), all successfully treated with antibiotics.
ABMT II: Fifteen (52%) proceeded to second transplant. The median number of days from the start of ABMT I until the start of ABMT II was 43 (range, 35-99 days). The second transplant was not performed in 14 patients due to progressive disease (seven patients), patient refusal and/or emotional distress (four patients), and earlier toxic death (three patients). For patients receiving the second transplant, chemotherapy dose reductions were unnecessary. The median length of hospitalization was 23 days (range, 17-31). There were no treatment-related deaths.
Hematologic recovery:
The median days of an ANC Ͻ500/l and of platelet counts Ͻ20 000/l were 12 (range, 7-23) and 12 (range, 5-18), respectively. Patients required a median of four units (range, 0-11) of packed RBC and 30 units (range, 10-90) of platelets until hematopoiesis was complete.
Non-hematologic toxicitiy:
Sixty-seven percent of patients developed mild to severe stomatitis and/or esophagitis requiring analgesia. Other moderate to severe toxicities (% patients) included: elevation of LFTs (40%), hearing loss (33%), peripheral neuropathy (20%), diarrhea (13%), and renal insufficiency (6%). Six patients developed bacteremias (Staphylococcus (four), Streptococcus (one), Klebsiella (one)) and two had C. difficile colitis during transplant.
Treatment response (Table 2)
Response after ABMT I: Three patients (10%) died early of treatment-related toxicity, thus 26 were evaluable for response after ABMT I. Most patients had either stable disease (eight patients) or developed disease progression (eight patients) despite high-dose chemotherapy. Six patients had achieved a PR (23%), two became PR surgically NED, and two were not formally assessed for response. There were no clinical complete responses. Best response after ABMT I or II: Of the 13 patients receiving both transplants and completely assessed after each, four had further tumor reduction after ABMT II. Two had clinical complete disappearance of disease, for a 15% conversion to CR after second transplant. Two others improved to PR surgically NED (one patient) and PR (one patient). Nine patients had no further measurable improvement.
Best response for the 26 patients treated with either one or two transplants included: two (8%) clinical CR, one CR surgically NED, five (19%) PR, and three (12%) PR surgically NED. Seven remained with stable (27%) and eight developed progressive (31%) disease despite high-dose chemotherapy.
Four patients underwent surgery for removal of residual masses, with teratoma (two patients) and necrotic disease (two patients) found on pathologic evaluation. One patient received radiotherapy to the mediastinum post-transplant.
Duration of response after ABMT:
Eight (28%) patients are currently progression-free (two CR after ABMT II, one CR surgically NED after ABMT II, two PR after ABMT II, two PR surgically NED after ABMT I, one SD after ABMT I), with a median follow-up of 60 months (range, 31-93) from ABMT I ( Table 3) . Three of four pure seminoma patients remain progression-free 30+ to 66+ months after transplant, including two with bad-risk features (absolute refractoriness to platinum, multiple relapses). Of the five long-term survivors with NSGCT, four were treated in first relapse with platinum-sensitive disease. The median PFS for the group as a whole is estimated at 4 months (95% CI, 3-29 months) (Figure 2) .
Eighteen relapses occurred, appearing a median of 4 months (range, 1-44) after ABMT I. Two relapses were late, occurring more than 2 years (at 28 and 44 months) after first transplant.
In addition to the eight patients alive and progressionfree, four others survive with disease 2-16 months after relapse. Seventeen (59%) patients have died: three (10%) of early toxicity and the rest of disease progression (median 6 months after relapse). The median survival for the group overall is estimated at 14 months (95% CI, 9 monthsinfinity) (Figure 3) .
Exploratory analyses discovered marginally significant differences in PFS and OS, when evaluated for age and number of transplants. Younger men appeared to have poorer survival (P = 0.08 for PFS; P = 0.06 for OS) overall, and those receiving two transplants lived longer progression-free than those receiving only one (P = 0.02 for PFS; P = 0.06 for OS). Of 10 patients with disease absolutely refractory to platinum-based chemotherapy, one (10%) remains alive and progression-free 30 months after ABMT. Four of those 10 received two transplants, while the others either developed disease progression (n = 5) or suffered toxic death (n = 1) before second transplant. Of the 10 patients with chemosensitive disease, seven are alive and five are progression-free (median PFS of the survivors is Figure 3 Overall survival of 29 males with relapsed or refractory testicular cancer receiving one or two high-dose chemotherapy cycles with autologous stem cell support. The estimated OS for the whole group is 14 months (95% CI 9 months-infinity).
46 months). Five of those 10 received two transplants, and three of those five remain progression-free.
Discussion
The design of high-dose curative regimens has relied on principles derived from laboratory and clinical observations. [27] [28] [29] [30] [31] [32] The correlation of drug dose and tumor response, the use of combination chemotherapy to prevent the rapid emergence of drug resistance, and the selection of agents with differing dose-limiting toxicities and mechanisms of action have all influenced trial design.
For hematologic malignancies with rapid doubling times and exquisite sensitivity to chemoradiotherapy, one highdose treatment course may be sufficient to obtain durable remissions in a significant fraction of patients. For most solid tumor malignancies however, marked heterogeneity in cellular kinetics, antigenic presentation, tumor microenvironment, and angiogenic potential play a major role in hindering the ability of a single high-dose chemotherapy regimen to eradicate disease. Despite peak concentrations, chemotherapeutic agents may be unable to diffuse throughout tumor masses due to inadequate access. Cytoreduction of tumor bulk by one high-dose treatment regimen may markedly improve the effectiveness of a second high-dose course due to improved vascular access, drug delivery, and tumor oxygenation. The efficacy of a sequential high-dose approach may be limited however, if substantial induction of drug resistance occurs, resulting in more effective detoxification of the chemotherapeutic agents employed.
The biology of metastatic gonadal testicular cancer is unique among solid tumors, especially in terms of its marked chemosensitivity. Even patients with bulky disease and massive tumor marker elevations at presentation may be cured with initial chemotherapy or salvaged with second-line treatment (including ABMT), often with surgical resection of residual masses. Whether multiple highdose chemotherapy cycles are needed to improve the likelihood of cure for germ cell patients who relapse or are refractory to first-line treatment has never been prospectively tested.
In this study, 29 men with relapsed or refractory germ cell tumors were enrolled on a clinical trial designed to administer two sequential high-dose courses of carboplatin and etoposide with autologous PBPC support. These patients had received significant prior chemotherapy (26 received уtwo regimens), had variable response to conventional platinum-containing regimens (10 were absolutely refractory and four were chemoresistant to platinum), and had suffered multiple relapses (13 had уtwo relapses) or had primary refractory disease (six patients) at time of ABMT. Only half (15/29) proceeded to second transplant; the others developed disease progression, refused further therapy, or died of toxicity after first transplant. Despite these adverse characteristics, eight (28%) patients are currently progression-free a median of 60 months from ABMT I. Of these eight, three obtained CR after ABMT II and two were rendered disease-free after ABMT I and surgical resection of residual disease. Five of these eight had platinum-sensitive disease and were treated in first relapse. There are a number of factors observed in this study, and in a review of the literature, that influenced outcome and/or are worthy of comment.
First, remission status after BMT appears prognostically important in terms of achieving long-term survival. [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] Unlike other solid tumors (eg breast, ovary) in which a clinical complete response prior to BMT is associated with prolonged progression-free survival, some testicular cancer patients with chemoresistant or refractory disease may be cured with attainment of CR after BMT and surgical resection of residual masses. Approximately one-third (range, 23-55%) of patients achieve CR after high-dose chemotherapy +/− surgery, and half of those responses are durable. [33] [34] [35] [36] [37] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] Conversely, failure to achieve CR results in disease relapse for most patients.
Second, resistance induced by conventional cisplatin dosing can be overcome with doses of carboplatin high enough to require hematopoietic support. [33] [34] [35] [36] 40, 43 Although cisplatin-resistant disease can respond to high-dose carboplatin, truly platinum-refractory disease is an adverse factor to achieving complete response and long-term survival. 35, [42] [43] [44] [45] 50 In a multicenter retrospective analysis (310 patients) to identify variables prognostic for response and survival, Beyer et al 42 determined that an increasing degree of cisplatin refractoriness was independently related to inferior responses and poorer failure-free survivals.
Third, although the value of tandem high-dose chemotherapy cycles is unproven, some studies suggest an improvement in terms of attaining CR, including the conversion of some partial to complete responses after second transplant. 35, 36, [39] [40] [41] [42] 46 Theoretically, a second high-dose treatment may consolidate a CR or allow achievement of CR if induced drug resistance is minimal after first BMT. Analysis of the literature is complicated however, by the fact that although a tandem transplant is planned, only about 60% actually receive both high-dose courses (Table 4) . Comparison of a tandem vs single transplant strategy is also difficult since there is only one large study reported for patients with refractory or relapsed disease receiving a single BMT. 45 Given these caveats, in studies 945 50 Relapsed C,Cb,E 15 0 11 + marrow C = cyclophosphamide; E = etoposide; Cb = carboplatin; I = ifosfamide; T = thiotepa; P = cisplatin. enrolling 20 or more patients with refractory and/or relapsed disease, the median CR rate is 32% (311 patients, eight trials) after a planned tandem transplant, which is not improved when compared to 31% CR (74 patients, one trial) after a single BMT. The number of patients alive and progression-free (median 28% PFS after tandem vs 33% PFS after single BMT) is likewise similar. In our study, those receiving two transplants lived longer progressionfree, with a strong trend toward improved survival, compared to those receiving only one. Unfortunately, Beyer's large retrospective multicenter study could not show whether one high-dose cycle of etoposide and carboplatin was comparable to two, even when an oxazaphosphorine was added to the regimen. 42 Fourth, surgical resection of residual masses is an important adjunct to high-dose chemotherapy. 35, 40, 42 Bone Marrow Transplantation Although these masses may more likely comprise mature teratoma than viable carcinoma (13% vs 5% in Beyer's study), complete excision can nonetheless enhance treatment outcome. Finally, late relapses (Ͼ2 years after BMT) do occur, although they are rare. 28, 42 In summary, patients with relapsed or refractory testicular cancer who benefit most from high-dose chemotherapy possess platinum-sensitive disease in first relapse and lack an extragonadal primary site. Patients who do poorly despite ABMT are those who present with a mediastinal NSGCT, have true cisplatin-refractory disease, develop disease progression within 1 month of completing platinumbased chemotherapy, and/or have markedly elevated ␤HCG levels at time of ABMT. 1, 34, 35, 40, 42 New treatment strategies and modalities are clearly needed for the latter group. Whether first-line dose-intensive therapy can lead to better control of intermediate or poor-risk testicular cancer, as defined by IGCCCG criteria, is being addressed in a multicenter phase III trial. 51 For patients with relapsed and refractory disease, much investigation is needed to develop more effective dose-intensive regimens for tumor cytoreduction, to optimize drug metabolism of high-dose chemotherapeutic agents, and to study the roles of sequence and schedule of administration to decrease acquired drug resistance. As with neuroblastoma, agents of growth and differentiation such as the retinoids may be worthy of consideration for maintenance therapy after high-dose chemotherapy for testicular cancers possessing retinoic acid receptors. 52, 53 
